News
NICE backs Opdivo for head and neck cancer
The National Institute for Health and Care Excellence (NICE) has recommended Bristol Myers Squibb’s (BMS) immunotherapy Opdivo (nivolumab) for routine use on the NHS as a treatment for metastatic and recurrent head and neck cancer.